Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience

Executive Summary

AstraZeneca PLC is keeping a tight lid on Phase III data for its biologic for severe asthma, benralizumab, other than to say it met its primary endpoint in a pair of pivotal trials – but the pharma hopes to offer differentiating efficacy from GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. biologics already approved for this indication when it unveils the full datasets at a scientific meeting later this year.


Related Content

Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market
Teva's Cinqair OK'd, But Narrower Use Than GSK's Nucala
What Future For Genentech's Lebrikizumab On Phase III Failure?


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst